admin

Santersus NucleoCapture Technology Designated as a Breakthrough Device for the Treatment of Sepsis by the US FDA

Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics …

Santersus NucleoCapture Technology Designated as a Breakthrough Device for the Treatment of Sepsis by the US FDA Read More »

Ageing and rejuvenation

It was shown that circulating NETs might support Inflamm-ageing chronic low grade inflammation typical of ageing, being common biological factor responsible for the decline and the onset of disease in the elderly. At Santersus, we are investigating the use of NucleoCapture to prevent inflamm-ageing and slow down functional decline in the elderly.

Santersus’ therapeutic technology helps to treat sepsis

Santersus has released an abstract at the International Society for Apheresis meeting (ISFA), which is being held virtually this year. The poster presentation entitled “Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis” was given by Dr. Andrew Aswani, the Chief Medical Officer of Santersus AG. Data clearly showed that the application …

Santersus’ therapeutic technology helps to treat sepsis Read More »